| Bioactivity | GSK-1292263 is an orally available GPR119 agonist with pEC50s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM)[1]. | ||||||||||||
| In Vivo | GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats[2]. Animal Model: | ||||||||||||
| Name | GSK1292263 | ||||||||||||
| CAS | 1032823-75-8 | ||||||||||||
| Formula | C23H28N4O4S | ||||||||||||
| Molar Mass | 456.56 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. X. Zhu, et al. GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment. [2]. Koji Matsumoto, et al. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. J Pharmacol Exp The |
GSK1292263
CAS: 1032823-75-8 F: C23H28N4O4S W: 456.56
GSK-1292263 is an orally available GPR119 agonist with pEC50s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.